$1.58 Billion is the total value of Camber Capital Management LP's 24 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 57.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| SPY | Buy | SPDR S&P 500 ETF Trustput | $376,845,000 | +55.8% | 1,500,000 | +50.0% | 23.88% | +102.9% |
| THC | Buy | TENET HEALTHCARE CORP | $94,473,000 | +22.1% | 5,750,000 | +43.8% | 5.99% | +59.0% |
| PRGO | New | PERRIGO CO PLC | $82,534,000 | – | 975,000 | +100.0% | 5.23% | – |
| EVHC | Buy | ENVISION HEALTHCARE CORP | $67,425,000 | +207.4% | 1,500,000 | +328.6% | 4.27% | +300.1% |
| HCA | New | HCA HEALTHCARE INC | $63,672,000 | – | 800,000 | +100.0% | 4.04% | – |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $63,504,000 | +44.9% | 1,400,000 | +7.7% | 4.02% | +88.6% |
| TSRO | New | TESARO INC | $51,640,000 | – | 400,000 | +100.0% | 3.27% | – |
| AMAG | Buy | AMAG PHARMACEUTICALS INC | $48,893,000 | +56.3% | 2,650,000 | +55.9% | 3.10% | +103.5% |
| RDUS | Buy | RADIUS HEALTH INC | $44,333,000 | +880.2% | 1,150,000 | +1050.0% | 2.81% | +1177.3% |
| ELGX | Buy | ENDOLOGIX INC | $35,680,000 | -2.1% | 8,000,000 | +6.7% | 2.26% | +27.4% |
| CLVS | New | CLOVIS ONCOLOGY INC | $16,480,000 | – | 200,000 | +100.0% | 1.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.